It is months since the chatter around Chinese sequencing giant BGI's initial public offering advanced from "will it happen?" to "when, where and how much?" Now Bloomberg has some answers. A $400 million IPO in Hong Kong is reportedly penciled in for the fourth quarter.
Carlsbad, CA's Isis Pharmaceuticals is touting mid-stage results for its in-development spinal muscular atrophy treatment, setting its sights on a Phase III study and sending its shares up about 15%.
GE Healthcare is readying space in Helsinki to host new startups, according to a report--a strategic way to tap into new technology as it continues to expand globally.
Merck KGaA went through a serious downsizing after its key multiple sclerosis drug candidate failed two years ago. But having rebounded faster than it expected, the German drugmaker is making some serious noise about being a more significant force.
Global Genomics Group is in the midst of an expansive cardiovascular study with hopes of finding new biomarkers and drug targets for coronary artery disease, and now the company has enlisted the help of CRO giant Quintiles to handle some of the necessary gene sequencing work.
The Michael J. Fox Foundation for Parkinson's Research is giving money to Ezose Sciences in New Jersey to look at the role that glycans play in Parkinson's disease.
Raptor Pharmaceutical's investigational Huntington's disease drug helped delay the progression of the brain-deteriorating disorder in a subset of patients, the company said, news that sent the biotech's shares soaring despite some lingering concerns with the data.
Patient groups are a potent force in the Duchenne muscular dystrophy field, where parents are known to take a vocal role in pushing regulators to help biotechs advance new therapies for the lethal genetic condition. Now one of those parents, J.P. Morgan vet Ilan Ganot, has reportedly been raising some serious cash to do deals on early-stage therapies that can be rushed through clinical development.
Novartis said its in-development skin cancer drug aced a Phase II study, completely eradicating the disease in some patients, and now the company plans to loop in regulators, possibly signaling an early FDA application for the treatment.
LONDON--AstraZeneca's top brass can't wait to start rubbing shoulders with scientists at its planned corporate campus in Cambridge, U.K. So the pharma giant has opted to send an advance team of scientists ahead to get the creative juices flowing early on.